vs

Side-by-side financial comparison of MSC INDUSTRIAL DIRECT CO INC (MSM) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

MSC INDUSTRIAL DIRECT CO INC is the larger business by last-quarter revenue ($965.7M vs $622.0M, roughly 1.6× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 5.4%, a 29.1% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 4.0%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -3.4%).

MSC Industrial Direct Co., Inc (MSC), through its subsidiaries, primarily MSC Industrial Supply Co., is one of the largest industrial equipment distributors in the United States, distributing more than 1.5 million metalworking and other industrial products.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

MSM vs RPRX — Head-to-Head

Bigger by revenue
MSM
MSM
1.6× larger
MSM
$965.7M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+0.8% gap
RPRX
4.8%
4.0%
MSM
Higher net margin
RPRX
RPRX
29.1% more per $
RPRX
34.4%
5.4%
MSM
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-3.4%
MSM

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MSM
MSM
RPRX
RPRX
Revenue
$965.7M
$622.0M
Net Profit
$51.8M
$214.2M
Gross Margin
40.7%
Operating Margin
7.9%
62.4%
Net Margin
5.4%
34.4%
Revenue YoY
4.0%
4.8%
Net Profit YoY
11.1%
2.9%
EPS (diluted)
$0.93
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MSM
MSM
RPRX
RPRX
Q4 25
$965.7M
$622.0M
Q3 25
$978.2M
$609.3M
Q2 25
$971.1M
$578.7M
Q1 25
$568.2M
Q4 24
$928.5M
$593.6M
Q3 24
$564.7M
Q2 24
$979.4M
$537.3M
Q1 24
$935.3M
$568.0M
Net Profit
MSM
MSM
RPRX
RPRX
Q4 25
$51.8M
$214.2M
Q3 25
$56.5M
$288.2M
Q2 25
$56.8M
$30.2M
Q1 25
$238.3M
Q4 24
$46.6M
$208.2M
Q3 24
$544.0M
Q2 24
$71.7M
$102.0M
Q1 24
$61.8M
$4.8M
Gross Margin
MSM
MSM
RPRX
RPRX
Q4 25
40.7%
Q3 25
40.4%
Q2 25
41.0%
Q1 25
Q4 24
40.7%
Q3 24
Q2 24
40.9%
Q1 24
41.5%
Operating Margin
MSM
MSM
RPRX
RPRX
Q4 25
7.9%
62.4%
Q3 25
8.6%
70.1%
Q2 25
8.5%
36.3%
Q1 25
94.0%
Q4 24
7.8%
60.9%
Q3 24
Q2 24
10.9%
50.2%
Q1 24
9.7%
-13.0%
Net Margin
MSM
MSM
RPRX
RPRX
Q4 25
5.4%
34.4%
Q3 25
5.8%
47.3%
Q2 25
5.9%
5.2%
Q1 25
41.9%
Q4 24
5.0%
35.1%
Q3 24
96.3%
Q2 24
7.3%
19.0%
Q1 24
6.6%
0.8%
EPS (diluted)
MSM
MSM
RPRX
RPRX
Q4 25
$0.93
$0.49
Q3 25
$1.02
$0.67
Q2 25
$1.02
$0.07
Q1 25
$0.55
Q4 24
$0.83
$0.46
Q3 24
$1.21
Q2 24
$1.27
$0.23
Q1 24
$1.10
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MSM
MSM
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$40.3M
$618.7M
Total DebtLower is stronger
$214.1M
$9.0B
Stockholders' EquityBook value
$1.4B
$9.7B
Total Assets
$2.5B
$19.6B
Debt / EquityLower = less leverage
0.16×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MSM
MSM
RPRX
RPRX
Q4 25
$40.3M
$618.7M
Q3 25
$56.2M
$938.9M
Q2 25
$71.7M
$631.9M
Q1 25
$1.1B
Q4 24
$57.3M
$929.0M
Q3 24
$950.1M
Q2 24
$25.9M
$1.8B
Q1 24
$22.2M
$843.0M
Total Debt
MSM
MSM
RPRX
RPRX
Q4 25
$214.1M
$9.0B
Q3 25
$168.8M
$8.9B
Q2 25
$285.0M
$8.0B
Q1 25
$7.6B
Q4 24
$289.9M
$7.6B
Q3 24
$7.6B
Q2 24
$299.8M
$7.6B
Q1 24
$294.5M
$6.1B
Stockholders' Equity
MSM
MSM
RPRX
RPRX
Q4 25
$1.4B
$9.7B
Q3 25
$1.4B
$9.6B
Q2 25
$1.4B
$9.5B
Q1 25
$9.8B
Q4 24
$1.4B
$10.3B
Q3 24
$10.3B
Q2 24
$1.4B
$9.8B
Q1 24
$1.4B
$9.9B
Total Assets
MSM
MSM
RPRX
RPRX
Q4 25
$2.5B
$19.6B
Q3 25
$2.5B
$19.3B
Q2 25
$2.5B
$18.3B
Q1 25
$17.6B
Q4 24
$2.5B
$18.2B
Q3 24
$18.0B
Q2 24
$2.5B
$17.7B
Q1 24
$2.5B
$16.1B
Debt / Equity
MSM
MSM
RPRX
RPRX
Q4 25
0.16×
0.92×
Q3 25
0.12×
0.93×
Q2 25
0.21×
0.84×
Q1 25
0.78×
Q4 24
0.21×
0.74×
Q3 24
0.74×
Q2 24
0.21×
0.78×
Q1 24
0.21×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MSM
MSM
RPRX
RPRX
Operating Cash FlowLast quarter
$29.4M
$827.1M
Free Cash FlowOCF − Capex
$7.4M
FCF MarginFCF / Revenue
0.8%
Capex IntensityCapex / Revenue
2.3%
Cash ConversionOCF / Net Profit
0.57×
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MSM
MSM
RPRX
RPRX
Q4 25
$29.4M
$827.1M
Q3 25
$702.6M
Q2 25
$151.6M
$364.0M
Q1 25
$596.1M
Q4 24
$101.9M
$742.5M
Q3 24
$703.6M
Q2 24
$143.5M
$658.2M
Q1 24
$78.7M
$664.6M
Free Cash Flow
MSM
MSM
RPRX
RPRX
Q4 25
$7.4M
Q3 25
Q2 25
$100.7M
Q1 25
Q4 24
$81.7M
Q3 24
Q2 24
$114.0M
Q1 24
$53.4M
FCF Margin
MSM
MSM
RPRX
RPRX
Q4 25
0.8%
Q3 25
Q2 25
10.4%
Q1 25
Q4 24
8.8%
Q3 24
Q2 24
11.6%
Q1 24
5.7%
Capex Intensity
MSM
MSM
RPRX
RPRX
Q4 25
2.3%
Q3 25
Q2 25
5.2%
Q1 25
Q4 24
2.2%
Q3 24
Q2 24
3.0%
Q1 24
2.7%
Cash Conversion
MSM
MSM
RPRX
RPRX
Q4 25
0.57×
3.86×
Q3 25
2.44×
Q2 25
2.67×
12.06×
Q1 25
2.50×
Q4 24
2.18×
3.57×
Q3 24
1.29×
Q2 24
2.00×
6.45×
Q1 24
1.27×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MSM
MSM

Segment breakdown not available.

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons